Teva GTC clinical trials
A division of Teva Pharmaceutical Industries, Ltd.
The registry lists 7 studies whose lead sponsor is Teva GTC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 7, 2013.
- 7studies on the registry
- 0open to participants now
What it is testing
The drugs Teva GTC’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 3
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 208
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 3 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
- Teva GTC7 studies
Something wrong with this grouping? Tell us on the Teva Pharmaceutical Industries, Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Teva Pharmaceutical Industries, Ltd. studies →
- Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's DiseaseTerminatedNCT01094613Phase 1/2
Sponsor listed in the registry: Teva GTC
- Open Label Extension Study to Protocol C2/13/DR-6MP-02WithdrawnNCT01433432Phase 2
Sponsor listed in the registry: Teva GTC
- Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease PatientsCompletedNCT00774982Phase 1
Sponsor listed in the registry: Teva GTC
- One Year Extension Study To Protocol C2/5/TZ:MS-05TerminatedNCT00464958Phase 1/2
Sponsor listed in the registry: Teva GTC
- Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)CompletedNCT00287157Phase 1
Sponsor listed in the registry: Teva GTC
- Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant SpasticityCompletedNCT00358293Phase 1/2
Sponsor listed in the registry: Teva GTC
- Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's DiseaseCompletedNCT00287170Phase 1/2
Sponsor listed in the registry: Teva GTC